Your browser doesn't support javascript.
loading
Illuminating and Radiosensitizing Tumors with 2DG-Bound Gold-Based Nanomedicine for Targeted CT Imaging and Therapy.
Sivasubramanian, Maharajan; Chu, Chia-Hui; Hsia, Yu; Chen, Nai-Tzu; Cai, Meng-Ting; Tew, Lih Shin; Chuang, Yao-Chen; Chen, Chin-Tu; Aydogan, Bulent; Liao, Lun-De; Lo, Leu-Wei.
Afiliación
  • Sivasubramanian M; Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan 35053, Taiwan.
  • Chu CH; Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan 35053, Taiwan.
  • Hsia Y; Institute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Zhunan 35053, Taiwan.
  • Chen NT; Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan.
  • Cai MT; Department of Cosmoceutics, China Medical University, Taichung 40402, Taiwan.
  • Tew LS; Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan.
  • Chuang YC; Department of Cosmoceutics, China Medical University, Taichung 40402, Taiwan.
  • Chen CT; Department of Biological Science and Technology, China Medical University, Taichung 406040, Taiwan.
  • Aydogan B; Department of Cosmoceutics, China Medical University, Taichung 40402, Taiwan.
  • Liao LD; Department of Radiation Oncology, Taipei Medical University Hospital, Taipei 110301, Taiwan.
  • Lo LW; Department of Radiology, The University of Chicago, Chicago, IL 60637, USA.
Nanomaterials (Basel) ; 13(11)2023 Jun 02.
Article en En | MEDLINE | ID: mdl-37299694
Although radiotherapy is one of the most important curative treatments for cancer, its clinical application is associated with undesired therapeutic effects on normal or healthy tissues. The use of targeted agents that can simultaneously achieve therapeutic and imaging functions could constitute a potential solution. Herein, we developed 2-deoxy-d-glucose (2DG)-labeled poly(ethylene glycol) (PEG) gold nanodots (2DG-PEG-AuD) as a tumor-targeted computed tomography (CT) contrast agent and radiosensitizer. The key advantages of the design are its biocompatibility and targeted AuD with excellent sensitivity in tumor detection via avid glucose metabolism. As a consequence, CT imaging with enhanced sensitivity and remarkable radiotherapeutic efficacy could be attained. Our synthesized AuD displayed linear enhancement of CT contrast as a function of its concentration. In addition, 2DG-PEG-AuD successfully demonstrated significant augmentation of CT contrast in both in vitro cell studies and in vivo tumor-bearing mouse models. In tumor-bearing mice, 2DG-PEG-AuD showed excellent radiosensitizing functions after intravenous injection. Results from this work indicate that 2DG-PEG-AuD could greatly potentiate theranostic capabilities by providing high-resolution anatomical and functional images in a single CT scan and therapeutic capability.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nanomaterials (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Nanomaterials (Basel) Año: 2023 Tipo del documento: Article País de afiliación: Taiwán Pais de publicación: Suiza